InnAccel

InnAccel uses a clinical immersion methodology adapted from the Stanford Biodesign framework, embedding engineers and entrepreneurs full-time inside Indian hospitals — including AIIMS and CMC Vellore — to document unmet needs before any product development begins. Each problem statement must be validated by multiple surgeons or intensivists across different hospital tiers before it enters the firm's internal R&D pipeline. This process generates the deal flow; InnAccel typically forms a company only after the clinical need is confirmed and an initial prototype has been built in its Bangalore lab.

InnAccel operates as a hybrid: it is a regulated venture fund that also houses an in-house engineering and regulatory team, making it closer to a venture studio for medtech. Unlike a standard VC, the firm does not just select and fund external startups — it identifies clinical needs, co-develops technologies, files patents, and navigates India's Central Drugs Standard Control Organization (CDSCO) clearance process internally before spinning the resulting product into a legally separate portfolio company. The fund then writes the first equity check into that entity.

InnAccel targets critical-care medical devices for the Indian hospital environment, with a focus on neonatal, maternal, and emergency medicine. Publicly disclosed portfolio devices include a bubble CPAP system for neonatal respiratory distress (Coeo Labs), a non-contact breast cancer screening tool (NIRAMAI), and a fetal heart rate monitor for low-resource labor wards. The firm explicitly avoids implantables and surgical robotics, staying within price points achievable for district-level hospitals and mid-tier private facilities.

Yes, InnAccel's structure as an early-stage fund means its initial investment is typically the first institutional capital, but it actively syndicates follow-on rounds with global impact investors and development finance institutions. Portfolio company NIRAMAI received follow-on funding from the USAID-backed India Investment Fund, and several InnAccel startups have drawn grants from the Bill & Melinda Gates Foundation and the Biotechnology Industry Research Assistance Council (BIRAC). The firm positions its early regulatory and engineering work as risk-reduction for later-stage venture syndicates.

While InnAccel is headquartered in Bangalore, its clinical immersion sites and portfolio companies span India's three largest medical-device manufacturing clusters: Bangalore, Chennai, and Hyderabad. The firm also draws clinical partners from major public and private hospitals in Delhi, Vellore, and Mumbai. Target end-markets are tier-2 and tier-3 Indian cities where critical-care infrastructure lags the metros — accordingly, device pricing is benchmarked to Indian government procurement budgets rather than US or EU reimbursement rates.

InnAccel maintains an in-house regulatory affairs unit that manages CDSCO classification, clinical trials under Indian Council of Medical Research guidelines, and manufacturing licensure for its portfolio companies. The firm's accelerator facility in Bangalore operates under ISO 13485 quality management certification, which allows it to function as a design and manufacturing hub that can transition portfolio products directly into regulated production. This is unusual for an early-stage investor and constitutes a core part of the firm's value proposition to both founders and downstream acquirers.

Investment decisions are driven by the founding team: Dr. A. Vijayarajan (Founder & Chief Mentor), Siraj Dhanani (Co-Founder & CEO), and Murali Krishnan (Co-Founder & CTO), per the firm's official structure. Vijayarajan's background combines executive roles at multinational device companies with academic leadership of the Stanford-India Biodesign program; the investment committee evaluates each potential portfolio company on the clinical validity of its target problem and the feasibility of achieving CDSCO clearance within a defined capital window.